Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Authors
Keywords
-
Journal
Cell Death Discovery
Volume 6, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-10
DOI
10.1038/s41420-020-00337-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
- (2019) Kai Zhang et al. CANCER LETTERS
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- (2019) T Bachelot et al. ANNALS OF ONCOLOGY
- Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
- (2019) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
- (2019) Lionel Low et al. Nature Communications
- Mutant p53 gain of function induces HER2 over-expression in cancer cells
- (2018) A. A. Román-Rosales et al. BMC CANCER
- Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
- (2018) Michael J. Duffy et al. BREAST CANCER RESEARCH AND TREATMENT
- New therapeutic strategies to treat human cancers expressing mutant p53 proteins
- (2018) Giovanni Blandino et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
- (2018) Ramesh Butti et al. Molecular Cancer
- Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion
- (2018) Ramona Schulz-Heddergott et al. CANCER CELL
- Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis
- (2018) Olga Fedorova et al. ONCOGENE
- Mutant p63 Affects Epidermal Cell Identity through Rewiring the Enhancer Landscape
- (2018) Jieqiong Qu et al. Cell Reports
- Essential Roles of E3 Ubiquitin Ligases in p53 Regulation
- (2017) Sanam Sane et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanical cues control mutant p53 stability through a mevalonate–RhoA axis
- (2017) Eleonora Ingallina et al. NATURE CELL BIOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab
- (2017) Reiki Nishimura et al. ONCOLOGY
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- The Roles of MDM2 and MDMX in Cancer
- (2016) Orit Karni-Schmidt et al. Annual Review of Pathology-Mechanisms of Disease
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
- (2016) Alejandro Parrales et al. NATURE CELL BIOLOGY
- A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
- (2016) Anthony Ferrari et al. Nature Communications
- ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
- (2016) Dun Li et al. Oncotarget
- Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
- (2015) J.-L. Zhang et al. GENETICS AND MOLECULAR RESEARCH
- Regulation of MDM2 Stability After DNA Damage
- (2015) Jiaqi Li et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes
- (2015) Taghipour Zahir Shokouh et al. MEDICINE
- Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis
- (2015) Alisha R. Yallowitz et al. MOLECULAR CANCER RESEARCH
- KMT Set7/9 affects genotoxic stress response via the Mdm2 axis
- (2015) Larissa Lezina et al. Oncotarget
- DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity
- (2015) Tatiana N Moiseeva et al. Oncotarget
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
- (2014) L. Silwal-Pandit et al. CLINICAL CANCER RESEARCH
- Functional interplay between MDM2, p63/p73 and mutant p53
- (2014) M H Stindt et al. ONCOGENE
- A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress
- (2014) D Li et al. Cell Death & Disease
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
- (2013) B. N. Rexer et al. CLINICAL CANCER RESEARCH
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- The rebel angel: mutant p53 as the driving oncogene in breast cancer
- (2012) D. Walerych et al. CARCINOGENESIS
- p53 mutations in cancer
- (2012) Patricia A. J. Muller et al. NATURE CELL BIOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab (Herceptin): Fig 1.
- (2011) J.J. Gemmete et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism
- (2011) Olga A. Fedorova et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Early onset HER2-positive breast cancer is associated with germlineTP53mutations
- (2011) Amal Melhem-Bertrandt et al. CANCER
- Histological, molecular and functional subtypes of breast cancers
- (2011) Gautam K. Malhotra et al. CANCER BIOLOGY & THERAPY
- 26S proteasome exhibits endoribonuclease activity controlled by extra-cellular stimuli
- (2011) Valentina A. Kulichkova et al. CELL CYCLE
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- (2011) D Li et al. CELL DEATH AND DIFFERENTIATION
- Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
- (2011) D. Li et al. MOLECULAR CANCER RESEARCH
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations
- (2010) J. R. F. Wilson et al. JOURNAL OF MEDICAL GENETICS
- Histological types of breast cancer: How special are they?
- (2010) Britta Weigelt et al. Molecular Oncology
- Molecular Stratification of Triple-Negative Breast Cancers
- (2010) C. M. Perou ONCOLOGIST
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Her2-positive breast cancer: Herceptin and beyond
- (2008) Windy Dean-Colomb et al. EUROPEAN JOURNAL OF CANCER
- Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
- (2008) D. Zhang et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started